Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Advanced Medicine, Bioprocessing - Upstream & Downstream

Manufacturing by Design

Thinking back as recently as 2010 and 2011, there were only a handful of organizations with serious intentions of bringing gene therapy products to the market. I remember when pharma companies and venture capitalists used to dismiss gene therapies as too complicated, risky and inefficient. 

Things have certainly changed. Close to $9 billion was invested globally in cell and gene therapies in 2018. Much of this has been driven by companies focusing on rare genetic diseases, which represent a relatively straightforward target if a single gene is responsible. These first “cures” have demonstrated that gene therapies can be effective and commercially viable.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Frederic Revah

Chief Executive Officer, Genethon.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register